

Canadian Retina Society  
Société canadienne de la Rétine

# HORIZON 2020

## 2015 Canadian Retina Society Meeting

Thursday February 26 to Sunday March 1, 2015  
Fairmont Chateau Whistler, Whistler, British Columbia, Canada

### Program

[cos-sco.ca/retina2015](http://cos-sco.ca/retina2015)



Canadian Ophthalmological Society  
Société canadienne d'ophtalmologie  
EYE PHYSICIANS AND SURGEONS OF CANADA | MÉDECINS ET CHIRURGIENS OPHTHALMOLOGISTES DU CANADA

*This program was co-developed by the Canadian Ophthalmological Society and the Canadian Retina Society in order to achieve scientific integrity, objectivity and balance as per the RCPSC's accreditation guidelines.*

# OUR SPONSORS

The Canadian Retina Society and the Canadian Ophthalmological Society gratefully acknowledge the participation of the following corporate sponsors, each of whom has provided an unrestricted educational grant in support of the meeting program.

---

## GOLD SPONSORS



Science For A Better Life

---

## SILVER SPONSORS



---

## BRONZE SPONSORS



---

## FRIENDS



# TABLE OF CONTENTS

Welcome .....	2
General Information .....	3
Guest Speakers .....	4
Dr. Mila Oh Memorial Lecture .....	6
Scientific Program .....	7
Thursday .....	7
Friday .....	7
Saturday .....	8
Sunday .....	9
Co-developed Accredited Symposia .....	10
Disclosures .....	11
Sponsors .....	12
Program at a Glance .....	Back Cover

# WELCOME

Dear Delegates, Guest Speakers and Sponsors,

It is with great pleasure that we welcome you to our 3rd Annual Canadian Retina Society Meeting – our yearly opportunity to come together to learn from each other.

We have created an exceptional scientific program delivered by our outstanding guest speakers from Europe, the US and Canada. We have an excellent balance of both medical and surgical topics, and this year’s schedule will allow you to optimize your learning, social and adventure experiences – all in the spectacular setting of North America’s finest mountain resort.

New this year is the presentation of the results of our first-ever, made-in-Canada “Canadian Preference and Trends (CAN-PAT) Survey.” We look forward to sharing these data with you, as they provide a fascinating glimpse into our daily choices in the clinic and OR.


If you are a CRS member, we hope you’ll join us for our CRS Business Meeting. The CRS Executive are busy all year supporting the needs of our members – come and learn what we’ve been working on!

We could not mount this meeting without the very generous support of our sponsors – we value our partnerships with each and every one. Please take the time to speak to their representatives. We also thank the staff of the Canadian Ophthalmological Society for their attention to the many behind-the-scenes details that allow this meeting to run smoothly.

We rely on your feedback to ensure that this meeting and future meetings meet your expectations. Please take the time to complete the evaluations and, of course, feel free to speak to any of us or the onsite staff.

Thank you for coming to Whistler – we wish you a wonderful meeting, great skiing and safe travels!

Sincerely,



Jim Whelan, MD, FRCSC  
*President, CRS*



Matt Tennant, MD, FRCSC  
*Co-chair, CPD Director*



Netan Choudhry, MD, FRCSC  
*Co-chair*





# GENERAL INFORMATION

## REGISTRATION

The Registration Desk is located in the Frontenac Foyer

Thursday, February 26	1600-1900	
Friday, February 27	0600-1030	1500-1830
Saturday, February 28	0600-1030	1500-1830
Sunday, March 1	0630-1000	

## BREAKFAST AND REFRESHMENTS

All breakfasts and refreshment breaks will be served in Frontenac BC.

## SCIENTIFIC SESSIONS

All scientific sessions and the CRS Business Meeting will be held in Frontenac A.

## SPEAKER INFORMATION

Guest speakers may visit the audio-visual technician for assistance with their presentations.

**Note:** All speakers are kindly asked to upload their final slides **at least one hour prior to their presentation time slot.**

## LEARNING OBJECTIVES

- Describe the identification and treatment of both common and rare medical and surgical diseases of the retina
- Describe the testing and treatment recommendations for patients with retinoblastoma
- Describe the current practice patterns of Canadian retina specialists

## CPD CREDITS

This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of The Royal College of Physicians and Surgeons of Canada, and approved by the Canadian Ophthalmological Society. Physicians may claim a maximum of 16 Section 1 credits.

Through an agreement between the Royal College of Physicians and Surgeons of Canada and the American Medical Association (AMA), physicians may convert Royal College MOC credits to AMA PRA Category 1 Credits™. Information on the process to convert Royal College MOC credit to AMA credit can be found at [Earning credit for participation in international activities.](#)

Date	Hours	Attended
Thursday, February 26, 2015	1.0	
Friday, February 27, 2015	6.0	
Saturday, February 28, 2015	6.0	
Sunday, March 1, 2015	3.0	
Total hours earned (1 hour = 1 Section 1 credit)	16.0	

Physicians should only claim credits commensurate with the extent of their participation in the activity.

## EVALUATION

Evaluation is a required component the RCPSC's MOC program. Please complete the evaluation for each session you attend in order to claim your CPD credits. The online evaluation is available at <http://crs2015.ca>. Please complete this evaluation by March 31, 2015. Evaluation stations are available in Frontenac A.

## We've Gone Mobile!

For detailed program information, scan the QR code or visit [Eventmobi.com/2015crs](http://Eventmobi.com/2015crs).

The free CRS meeting app can be viewed on any mobile device or computer.



## GUEST SPEAKERS



**Alice Y.Y. Cheng, MD, FRCPC**

*Endocrinologist, Trillium Health Partners and St. Michael's Hospital  
Assistant Professor, Department of Medicine, University of Toronto*



**Allen C. Ho, MD**

*Director of Retina Research, Wills Eye Hospital  
Professor of Ophthalmology, Thomas Jefferson University School of Medicine*



**Dean Elliott, MD**

*Associate Director, Retina Service  
Stelios Evangelos Gragoudas  
Associate Professor of Ophthalmology, Massachusetts Eye and Ear Infirmary and Harvard Medical School*



**Peter J. Lin, MD, CCFP**

*Director Primary Care Initiatives, Canadian Heart Research Centre*



**Brenda L. Gallie, MD, FRCSC, CM, OOnt**

*Director, Retinoblastoma Program, SickKids Hospital, Toronto  
Adjunct Scientist and Staff, Ocular Oncology Clinic, Princess Margaret Cancer Centre*



**Theodor Stappler, MD**

*Consultant vitreoretinal surgeon and clinical lead in surgical retina  
St Paul's Eye Unit, Royal Liverpool University Hospital*



**Professor Dr. Florian Gekeler**

*Chair, Department of Ophthalmology  
Stuttgart Hospital*

## Foundation Fighting Blindness

The Foundation Fighting Blindness is restoring hope and sight. Ophthalmologists like you play a key role in our mission to lead this fight against blindness by advancing retinal disease research, education and public awareness. As Canada's largest charity for sight-saving research, we have invested over \$28 million at universities and hospitals across the country, and created a national patient registry to further enable clinical research. We also offer a life-changing educational experience for your patients and their families at our annual **Vision Quest** conference, held in cities across Canada.

*“As the co-chairs of Vision Quest 2014 in Calgary, we witnessed how eager our patients were to be more engaged with their care. In fact, community interest was so high, we’ve volunteered to host another Vision Quest meeting in 2015. Working with the Foundation Fighting Blindness inspires hope that we can change the future of eye health together.”*

– Geoff Williams, MD, FRCSC; Amin Kherani, MD, FRCSC

Help us restore hope and sight. Visit [ffb.ca](http://ffb.ca) or call **1.800.461.3331**.

**Sharon Colle, President & CEO**  
Foundation Fighting Blindness



The **FOUNDATION**  
**FIGHTING BLINDNESS**  
You'll see: **results.**

Canadian **Retina** Society  
Société canadienne de la **Rétine**

*Stay tuned for details about the*  
**2016 Canadian Retina Society Meeting!**

# DR. MILA OH MEMORIAL LECTURE

Saturday, February 28, 2015

1600-1650

## One Retinoblastoma World: A consortium for optimized care everywhere

Brenda L. Gallie, MD, FRCSC, CM, OOnt



Mila Oh (1969–2010)

It is with great pride that we present the Dr. Mila Oh Memorial Lecture. In 1995, Mila was accepted as a resident in the Department of Ophthalmology at McGill University. From that year on, she was considered a star. She was intelligent, hardworking, and had a great sense of humour. Mila was Chief Resident in 1999 before heading to Duke University to pursue vitreoretinal fellowship studies for the next two years. Upon her return to Montreal, Mila worked diligently at the Royal Victoria Hospital in Montreal. She brought passion, commitment and firm opinions to the management of patients, to the training of young ophthalmologists and the betterment of her department. While battling cancer, Mila assumed the role of Interim Program Director, offering her time to relieve a colleague who was also fighting cancer. Mila was also a member of the COS clinical practice guideline committee on diabetic retinopathy. Tragically, she died before the guidelines were completed. The final published guidelines were dedicated to her memory. To those who were blessed to work with Mila, there was no better example of devotion, and no better example of a team player. She was a very dear friend and is greatly missed by her family, patients and colleagues.

*With thanks to Dr. Oh's husband Ken Hunt for the photo of Mila, and her colleagues Drs. Miguel Burnier, Jean Deschênes and Michael Kapusta for sharing their memories.*



We are honoured to welcome Dr. Brenda Gallie to present this lecture. For 40 years, Dr. Gallie and her research teams have focused on optimizing care for retinoblastoma; learning fundamental principles of cancer, genetics and translational medicine from this rare disease. Retinoblastoma research has led to the recognition that cancer is a genetic disease; showed how to find tumor suppressor genes; illustrated the role of progressive genomic instability from normal to cancer; and developed top-quality molecular diagnostics in a business model with the patient foremost. For optimal care and outcomes, they developed the first ever national guidelines for care for Canada, now adopted in Kenya. With worldwide stakeholders, including retinoblastoma survivors, One Retinoblastoma World (1RBW) has emerged with a constellation model of collaborative governance that supports multi-organization partnerships and inspires innovative thinking and problem solving.

***We thank The Retina Foundation of Canada  
for their generous support of this lecture.***





# SCIENTIFIC PROGRAM

## Thursday, February 26, 2015

---

### 1200-1600 Arrivals

Industry advisory boards

---

### 1620-1625 Welcome – Jim Whelan and Matt Tennant

---

### 1625-1725 Scientific session #1

At the end of this session, participants will be able to:

- Understand how to identify the presentations of a variety of unusual retinal pathologies
- Know what special tests should be performed to confirm the diagnosis for rare retinal diseases
- Recognize the imaging features associated with retinal disease

---

### 1625-1725 Mystery cases – Moderator: Netan Choudhry

---

### 1730-1900 CRS Business Meeting

---

### 1900-2030 Welcome Reception

Portobello Restaurant, Fairmont Chateau Whistler

Please join us for a glass (or two) of Whistler's finest micro-brewery beer or select wine, to welcome colleagues and friends to this year's meeting.

## Friday, February 27, 2015

---

### 0600-0630 Breakfast

---

### 0630-0900 Scientific session #2

At the end of this session, participants will be able to:

- Gain familiarity with the presentation, diagnosis, and management of vitreoretinal lymphoma
- Understand new and potential treatments for diabetic retinopathy
- Review pathological and imaging features of eyes with unique response to selected anti-VEGF therapy

---

### 0630 Welcome and introductions – Matt Tennant

---

### 0635 Vitreoretinal lymphoma – Dean Elliott

---

### 0655 Q & A

---

### 0705 Diabetic retinopathy: current and investigational therapies – Allen C. Ho

---

### 0730 Q & A

---

### 0740 Anti-VEGF switch cases – Moderator: Netan Choudhry; Panelists: Allen C. Ho, Dean Elliott

---

### 0900 Refreshment break

---

### 0910-1010 Co-developed accredited symposium: Multidisciplinary care of diabetic macular edema

At the end of this session, participants will be able to:

- Understand the most recent clinical trial data for anti-VEGF medication in the treatment of DME
- Identify the gaps in care for patients with DME and create tools to help bridge these gaps
- Engage multiple stakeholders to improve the diagnosis and treatment of DME
- Better leverage the key roles played by family physicians, endocrinologists and ophthalmologists in the management of DME
- Describe the multifactorial approach to diabetes management as outlined in the Canadian Diabetes Association 2013 clinical practice guidelines

---

### 0910 Welcome and introductions – Geoff Williams

---

### 0920 DME trials – David Maberley

---

### 0930 Diabetes 101 – Alice Y.Y. Cheng

---

### 0940 DME – Bridging the gaps – Peter J. Lin

---

### 0950 Panel discussion – Ask the ophthalmologist / endocrinologist / family doctor – Panelists: David Maberley, Alice Y.Y. Cheng, Peter J. Lin

*\* This session was co-developed by the Canadian Ophthalmological Society and Bayer and was planned to achieve scientific integrity, objectivity and balance.*

---

### 1010 Adjourn

---

**1530-1600 Refreshment break**

---

**1600-1830 Scientific session #3**

At the end of this session, participants will be able to:

- Understand basic principles and controversial topics in the management of open globe injuries
- Understand the risk factors, findings, and surgical management of retinal detachment due to proliferative vitreoretinopathy
- Raise awareness of an individualized management of ocular trauma
- Understand how tamponades work and their advantages and limitations
- Become more knowledgeable about current treatment options for complex retinal detachments

---

**1600 Introduction** – *Jim Whelan*

---

---

**1605 Ocular management of trauma** – *Dean Elliott*

---

---

**1625 Q & A**

---

---

**1635 Medical management of PVR** – *Dean Elliott*

---

---

**1655 Q & A**

---

---

**1705 An individualized approach to post-traumatic exploratory vitrectomy in children and young adults** – *Theodor Stappler*

---

---

**1725 Q & A**

---

---

**1735 Molecular design for novel ocular tamponades** – *Theodor Stappler*

---

---

**1800 Panel discussion: Management of complex retinal detachment** – *Panelists: Theodor Stappler, Dean Elliott, Matt Tennant, Jim Whelan, Netan Choudhry*

---

---

**1830 Adjourn**

---

**1900-2200 Dinner**

Grand Hall, Squamish Lil'wat Cultural Centre

Located only a 2-minute walk from the Fairmont Chateau

Whistler, this historic venue offers you the opportunity to explore featured exhibits and the creative works of the artists in residence while you enjoy a reception-style dinner.

## Saturday, February 28, 2015

---

**0600-0630 Breakfast**

---

**0630-0900 Scientific session #4**

At the end of this session, participants will be able to:

- Review current investigational cell therapy approaches for age-related macular degeneration
- Understand the benefits and detractions of stem cell implantation for geographic atrophy
- Discuss the evidence for and current experience with a visual prosthesis system for severe retinal degeneration
- Understand the specifics of subretinal vs. epiretinal implants and its specific surgical challenges
- Develop an overview over currently achievable results with electronic visual implants
- Have an in-depth knowledge of how exactly the anatomical structures are affected by modern surgical and pharmacological intervention

---

**0630 Welcome and introductions** – *Jim Whelan*

---

---

**0635 Cell therapy for age-related macular degeneration** – *Allen C. Ho*

---

---

**0700 Q & A**

---

---

**0710 The Argus® II Retinal Prosthesis for severe retinitis pigmentosa** – *Allen C. Ho*

---

---

**0735 Q & A**

---

---

**0745 Subretinal implants: surgical challenges and visual outcomes** – *Florian Gekeler*

---

---

**0810 Q & A**

---

---

**0820 Surgical and pharmacological effects on the vitreoretinal interface** – *Theodor Stappler*

---

---

**0845 Q & A**

---

---

**0900 Refreshment break**

---

**0910-1010 Co-developed accredited symposium: Management of macular holes 2015**

At the end of this session, participants will be able to:

- Discuss recent advances in the management of macular holes involving the use of ocriplasmin, surgical techniques, and imaging technologies
- Classify macular holes using the OCT-based anatomic classification system and leverage this information when making treatment decisions

- Identify patient baseline characteristics, such as macular hole size and presence of VMT, that affect treatment decisions
- Assess the benefits and risks of surgical techniques, such as ILM peeling, when managing macular holes
- Optimize the management of macular holes in difficult-to-treat patients

**0910 Macular holes: review of recent literature**  
– Netan Choudhry

**0920 OCT reading: identifying and measuring macular holes** – Allen C. Ho

**0935 Panel discussion based on macular hole management** – Moderators: David Chow and Michael Kapusta

*\* This session was co-developed by the Canadian Ophthalmological Society and Alcon and was planned to achieve scientific integrity, objectivity and balance.*

**1010 Adjourn**

**1530-1600 Refreshment break**

**1600-1830 Scientific session #5**

At the end of this session, participants will be able to:

- Understand that retinoblastoma is the same disease, everywhere and that successful care for retinoblastoma depends on early diagnosis, expertise and realistic plans for the newly diagnosed child, and global networking
- Understand that the whole child with retinoblastoma is more important than the eye
- Appreciate that clinical trials are difficult in rare diseases, but may be replaced by a learning health system
- Understand the benefits and harms of innovation using the analysis of the Gartner Hype Cycle as illustration, and how formal research fails children
- Know the mechanisms leading to different types of cataracts post-vitreotomy
- Understand the impact of high-altitude medicine to general physiology and the eye

**1600 Introductions** – Matt Tennant and John Galic, President, The Retina Foundation of Canada

**1605 Dr. Mila Oh Memorial Lecture: One Retinoblastoma World: A consortium for optimized care everywhere** – Brenda L. Gallie

**1645 Q & A**

**1655 The desperate need for evidence in quality care for retinoblastoma** – Brenda L. Gallie

**1720 Q & A**

**1730 Why is there cataract after vitrectomy?**  
– Florian Gekeler

**1750 Q & A**

**1800 High-altitude ophthalmology**  
– Florian Gekeler

**1820 Q & A**

**1830 Adjourn**

**1900-2000 Ice Bar**

Portobello Restaurant Patio, Fairmont Chateau Whistler

Please join us for a drink and a chat with colleagues and friends.

## Sunday, March 1, 2015

**0630-0700 Breakfast**

**0700 Introduction** – Jim Whelan

**0705 The Foundation Fighting Blindness**  
– Ann Morrison, Director of Philanthropy

**0710-1000 Scientific session #6**

At the end of this session, participants will be able to:

- Understand the current treatment patterns of retina specialists across Canada
- Review unique surgical management techniques for vitreoretinal diseases

**0710 Expanding the Dialogue: Results of the Canadian Preferences and Trends (CAN-PAT) Survey** – Jim Whelan and Netan Choudhry

**0755 Q & A**

**0810 Interesting surgical cases**  
Panelists: Matt Tennant, Netan Choudhry

**1000 Adjourn**

## Multidisciplinary Care of Diabetic Macular Edema

### SCIENTIFIC PLANNING COMMITTEE

Dr. Geoff Williams, Chair  
Dr. Matt Tennant  
Dr. David Maberley  
Dr. Amin Kherani, COS representative



Science For A Better Life

- 0910 Welcome and introductions – Geoff Williams
- 0920 DME trials – David Maberley
- 0930 Diabetes 101 – Alice Y.Y. Cheng
- 0940 DME – Bridging the gaps – Peter J. Lin
- 0950 Panel discussion – Ask the ophthalmologist / endocrinologist / family doctor

*Light snacks and refreshments will be served.*

### Learning Objectives

At the end of this session, participants will be able to:

- Understand the most up-to-date clinical trial data for anti-VEGF use in the treatment of DME
- Describe the multifactorial approach to diabetes management as outlined in the Canadian Diabetes Association 2013 clinical practice guidelines
- Identify the gaps in care for patients with DME and create tools to help bridge these gaps
- Engage multiple stakeholders to improve the diagnosis and treatment of DME
- Better leverage the key roles played by family physicians, endocrinologists and ophthalmologists in the management of DME

### SPEAKERS



Dr. David Maberley  
Ophthalmologist



Dr. Alice Y.Y. Cheng  
Endocrinologist



Dr. Peter J. Lin  
Family physician

**ACCREDITATION STATEMENT** This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of The Royal College of Physicians and Surgeons of Canada, and approved by the Canadian Ophthalmological Society. Physicians may claim a maximum of 1 Section 1 credits. Through an agreement between the Royal College of Physicians and Surgeons of Canada and the American Medical Association (AMA), physicians may convert Royal College MOC credits to AMA PRA Category 1 Credits™. Information on the process to convert Royal College MOC credit to AMA credit can be found at <http://www.ama-assn.org/ama/pub/education-careers/continuing-medical-education/physicians-recognition-award-credit-system/other-ways-earn-ama-pra-category/international-programs.page>.

Physicians should only claim credits commensurate with the extent of their participation in the activity.

This symposium was co-developed with Bayer and was planned to achieve scientific integrity, objectivity and balance. The use of the partner logo is ethically permissible.

## Management of Macular Holes 2015

### SCIENTIFIC PLANNING COMMITTEE

Dr. David Chow, Co-chair  
Dr. Michael Kapusta, Co-chair  
Dr. Brad Hinz, COS representative



- 0910 Macular holes: Review of recent literature – Netan Choudhry
- 0925 OCT reading: Identifying and measuring macular holes – Allen Ho
- 0935 Panel discussion based on macular hole management – Moderators: David Chow and Michael Kapusta

*Light snacks and refreshments will be served.*

### Learning Objectives

At the end of this session, participants will be able to:

- Discuss recent advances in the management of macular holes involving the use of ocriplasmin, surgical techniques, and imaging technologies
- Classify macular holes using the OCT-based anatomic classification system and leverage this information when making treatment decisions
- Identify patient baseline characteristics, such as macular hole size and presence of VMT, that affect treatment decisions
- Assess the benefits and risks of surgical techniques, such as ILM peeling, when managing macular holes
- Optimize the management of macular holes in difficult-to-treat patients

### FACULTY



Dr. Netan Choudhry



Dr. David Chow



Dr. Allen Ho



Dr. Michael Kapusta

**ACCREDITATION STATEMENT** This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of The Royal College of Physicians and Surgeons of Canada, and approved by the Canadian Ophthalmological Society. Physicians may claim a maximum of 1 Section 1 credits. Through an agreement between the Royal College of Physicians and Surgeons of Canada and the American Medical Association (AMA), physicians may convert Royal College MOC credits to AMA PRA Category 1 Credits™. Information on the process to convert Royal College MOC credit to AMA credit can be found at <http://www.ama-assn.org/ama/pub/education-careers/continuing-medical-education/physicians-recognition-award-credit-system/other-ways-earn-ama-pra-category/international-programs.page>.

Physicians should only claim credits commensurate with the extent of their participation in the activity.

This symposium was co-developed with Alcon and was planned to achieve scientific integrity, objectivity and balance. The use of the partner logo is ethically permissible.

# DISCLOSURES

The scientific planning committee members and guest speakers disclosed the following affiliations (financial or otherwise) with commercial organizations during the past two years. Please note: this information was current at the time of press. Any added information will be available on site.

## CRS Meeting Scientific Planning Committee Members

### Netan Choudhry

*Grant/research support:*  
Alcon  
*Consulting and honoraria:*  
Alcon, Optos, Novartis, Allergan, Bayer  
*Scientific Advisory Board:*  
Alcon, Allergan, Bayer, Novartis, Bausch & Lomb

### Matthew Tennant

*Grant/research support:*  
Bayer, Novartis  
*Speaking honoraria:*  
Novartis  
*Scientific Advisory Board:*  
Bayer

### James Whelan

*Grant/research support:*  
Novartis  
*Membership on an advisory panel, committee or board of directors:*  
Angiogenesis Foundation

## Co-developed Accredited Symposia Scientific Planning Committee Members

### David Chow

*Grant/research support:*  
Bayer, Clarion  
*Participation in clinical trial:*  
Alcon, Bayer, Novartis  
*Employment/honoraria/consulting fees/in-kind compensation:*  
Alcon, Novartis, Bayer, Allergan, Synergetics, Katalyst, DORC  
*Investments (stock options etc):*  
Synergetics, Arctic Dx, Katalyst  
*Membership on an advisory panel, committee or board of directors:*  
Alcon, Bayer, Katalyst, DORC

### Brad Hinz

*Participation in clinical trial:*  
Bayer, Novartis

### Michael Kapusta

*No affiliation (financial or otherwise) with a commercial organization*

### Amin Kherani

*Grant/research support:*  
Novartis  
*Participation in clinical trial:*  
Novartis, Alcon, Bayer, Abbvie, Abbott, Ophthotech  
*Investments (stock options etc):*  
MD Collaborate  
*Membership on an advisory panel:*  
Novartis, Bayer, Bausch & Lomb, Allergan, Alcon

### David Maberley

*Participation in clinical trial:*  
Bayer, Novartis, Ophthotech  
*Employment/honoraria/consulting fees/in-kind compensation:*  
Abbvie, Alcon, Bayer, Novartis  
*Membership on an advisory panel, committee or board of directors:*  
Allergan, Alcon

### Geoff Williams

*Grant/research support:*  
Novartis  
*Participation in clinical trial:*  
Novartis, Bayer  
*Investments (stock options etc):*  
Arctic Dx, MD Collaborate  
*Membership on an advisory panel:*  
Bayer, Alcon, Novartis

## Guest Speakers

### Alice Y.Y. Cheng

*Participation in clinical trial:*  
Amgen, Sanofi, Pfizer, Eli Lilly, Novo Nordisk  
*Speaking honoraria:*  
AstraZeneca, Eli Lilly, Boehringer Ingelheim, Merck, Novo Nordisk, Sanofi, Janssen, Abbott, Becton Dickinson, Servier  
*Membership on advisory committee:*  
AstraZeneca, Eli Lilly, Boehringer Ingelheim, Merck, Novo Nordisk, Sanofi, Janssen, Abbott, Amgen

### Dean Elliott

*Grant/research support:*  
Ocata, Juvenile Diabetes  
*Participation in clinical trial:*  
Ocata, Juvenile Diabetes  
*Consultant:*  
Alimera, Avalanche, Bausch & Lomb, Biogen, ReNeuron, Thrombogenesis  
*Scientific advisory board:*  
Acucela

### Brenda L. Gallie

*No affiliation (financial or otherwise) with a commercial organization*

### Florian Gekeler

*Grant/research support:*  
Retinal Implant, AG  
*Participation in clinical trial:*  
Retinal Implant, AG  
*Employment/honoraria/consulting fees/in-kind compensation:*  
Retinal Implant, AG  
*Investments (stock options etc):*  
Retinal Implant, AG  
*Membership on an advisory panel, committee or board of directors:*  
Retinal Implant, AG

### Allen C. Ho

*Grant/research support:*  
Alcon, Allergan, Janssen, J&J, Genentec, Regeneron, Thombogenics  
*Employment/honoraria/consulting fees/in-kind compensation:*  
Alcon, Allergan, Janssen, J&J, Genentec, Regeneron, Thombogenics

### Peter J. Lin

*Employment/honoraria/consulting fees/in-kind compensation:*  
AstraZeneca, Takeda, Boehringer Ingelheim, Eli Lilly, Sanofi, Janssen, Merck, Pfizer, Servier, Abbott, Forest Laboratories, Novartis, Purdue, Allergan


### Theodor Stappler

*Grant/research support:*  
Geuder AG (Germany), Alcon (UK)  
*Patent holder (research team):*  
Geuder AG (Germany)

# Enhancing Sight. Enhancing Lives.

## LEADING THE WAY IN EYE CARE

Alcon is the global leader in eye care because we are passionate about helping people see better. We are dedicated to enhancing lives by enhancing sight, one of our most precious senses. We provide patients innovative products with the goal to deliver the best patient outcomes. With our three businesses – surgical, pharmaceutical and vision care – we offer the widest spectrum of industry-leading products that address the full life cycle of eye care needs. We are proud of being a trusted partner to professionals across the globe.



**Alcon**<sup>®</sup>

a Novartis company

E  
N H  
A N C  
I N G S  
I G H T E  
N H A N C I  
N G L I V E S

Enhancing Sight. Enhancing Lives.  
LEADING THE WAY IN EYE CARE

Alcon is the global leader in eye care because we are passionate about helping people see better. We are dedicated to enhancing lives by enhancing sight, one of our most precious senses. We provide patients innovative products with the goal to deliver the best patient outcomes. With our three businesses – surgical, pharmaceutical and vision care – we offer the widest spectrum of industry-leading products that address the full life cycle of eye care needs. We are proud of being a trusted partner to professionals across the globe.

**Alcon**<sup>®</sup>

a Novartis company



## You need commitment, focus and passion to find new ways to fight the diseases of this world: innovation is at the heart of it.

*Science For a Better Life.* Our commitment is to bring to patients around the world quality medicines for use in diagnosing, combating and preventing disease.

Every day we work against time, researching new pathways, new molecules, new technologies – complementing our own capabilities with the expertise of innovative partners from science and industry.

Bayer is proud of its commitment and research into diseases of the eye, and supporting groups like the Canadian Retina Society is one great example of Bayer putting its mission of Science For A Better Life into action.

For more information about Bayer, visit [www.bayer.ca](http://www.bayer.ca)





# Bayer HealthCare



Science For A Better Life

Dear Delegate,

On behalf of Bayer Ophthalmology, we hope your meetings in the coming days are insightful, rewarding and inspiring.

Should you have any questions please feel free to reach out to any of our Team who are here in Whistler during the meeting.

We look forward to meeting you over the coming days.

Sincerely,

**Taflyn Hornibrook**  
Bayer Ophthalmology

On Site Bayer Ophthalmology Team	
<p><b>Taflyn Hornibrook</b> Business Unit Head – Ophthalmology</p> <p>Email: taflyn.hornibrook@bayer.com Phone: (647) 227-8348</p>	<p><b>Lynne Rose Brunck</b> Sr. Medical Advisor</p> <p>Email: lynne.brunck@bayer.co Phone: (416) 570-2850</p>
<p><b>Nick Mavroidis</b> National Business Development Manager – Eylea</p> <p>Email: nick.mavroidis@bayer.com Phone: (647) 522-2286</p>	<p><b>Pablo Velazquez-Martin, MD</b> Medical Advisor</p> <p>Email: pablo.velazquez-martin@bayer.com Phone: (416) 436-7621</p>
<p><b>Amy Bowes</b> Sr. Market Manager – Eylea</p> <p>Email: amy.bowes@bayer.com Phone: (416) 970-1684</p>	<p><b>Stephanie Howard</b> Key Account Specialist</p> <p>Email: Stephanie.howard@bayer.com Phone: (403) 461-3946</p>
<p><b>Joe Connolly</b> Assoc. Market Manager – Eylea</p> <p>Email: joseph.connolly@bayer.com Phone: (416) 580-6180</p>	<p><b>Dan Gillis</b> Key Account Specialist</p> <p>Email: dan.gillis@bayer.com Phone: (226) 402-4568</p>
<p><b>Heather Iaccino</b> National Sales Manager – Ophthalmology</p> <p>Email: heather.iaccino@bayer.com Phone: (416) 258 9772</p>	<p><b>Jamie Stretch</b> Key Account Specialist</p> <p>Email: Jamie.stretch@bayer.com Phone: (289) 834-2732</p>



Novartis Pharmaceuticals Canada Inc. is one of the country's leading healthcare companies committed to improving the health of Canadians.

We discover and develop medicines that make a real difference.

There can be no delay.

Patients are waiting.



[www.novartis.ca](http://www.novartis.ca)




---

Novartis Group companies employ approximately 130,000 full-time-equivalent associates and sell products in more than 150 countries around the world.

---

Novartis Pharmaceuticals Canada Inc., a leader in the healthcare field, is committed to the discovery, development and marketing of innovative products to improve the well-being of all Canadians. In 2013, the company invested close to \$100 million in research and development in Canada. Novartis Pharmaceuticals Canada Inc. employs more than 600 people in Canada. For further information, please consult [www.novartis.ca](http://www.novartis.ca).

Located in Dorval, Quebec, Novartis Pharmaceuticals Canada Inc. is an affiliate of Novartis AG, which provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel,

Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and over-the-counter products. Novartis is the only global company with leading positions in these areas. In 2013, the Group achieved net sales of USD 57.9 billion, while R&D throughout the Group amounted to approximately USD 9.9 billion (USD 9.6 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 130,000 full-time-equivalent associates and sell products in more than 150 countries around the world. For more information, please visit <http://www.novartis.com>.



[www.novartis.ca](http://www.novartis.ca)

**Allergan is a multi-specialty health care company established more than 60 years ago with a commitment to uncover the best of science and develop and deliver innovative and meaningful treatments to help people reach their life's potential.**

Today, we have approximately 10,000 highly dedicated and talented employees, global marketing and sales capabilities with a presence in more than 100 countries, a rich and ever-evolving portfolio of pharmaceuticals, biologics, medical devices and over-the-counter consumer products, and state-of-the-art resources in R&D, manufacturing and safety surveillance that help millions of patients see more clearly, move more freely and express themselves more fully.

From our beginnings as an eye care company in 1950, Allergan has a heritage in discovering and developing new therapeutic agents to protect and preserve vision. Eye care professionals and patients rely on Allergan products to treat a variety of eye conditions, including glaucoma, dry eye, and external eye diseases. The Allergan Retina Division introduced retinal specialists to the world's first biodegradable intravitreal implant and is committed to advancing treatment options for posterior segment diseases with multiple investigational therapies. Allergan is proud to support the patients and physicians who rely on our products and the employees and communities in which we live and work. In Canada, Allergan employs more than 200 people and has a corporate head office in Markham, Ontario.



85 Enterprise Blvd., Suite 500, Markham, Ontario L6G 0B5 Telephone: (905) 940-1660 Facsimile: (905) 940-1902



## Each day, we have 14 billion little reminders to continue advancing eye health.

From the moment we open our eyes and start to view the possibilities of each new day, we look at how we can improve the well-being of the world's 14 billion eyes. Will this be the day when one of us unlocks a way to eliminate visual impairment in newborns? Or strikes upon a treatment that actually helps the eye heal itself? To us, these are not some distant hopes. They are the daily questions that add new urgency to all we do and everything we see for the future. We're Bausch + Lomb, a company solely focused on advancing the vision and care of the world's eyes.

[Bausch.com](http://Bausch.com)

© 2014 Bausch & Lomb Incorporated. BLS05655 TP9960

**BAUSCH + LOMB**  
See better. Live better.

**INNOVA**, Canada's leading distributor of ophthalmic, diagnostic, and surgical instruments is proud to be corporate sponsor of this year's Canadian Retina Society meeting.

With specialty representatives from coast to coast, and support from our exceptional service team, our customers have confidence in the wide range of products available from INNOVA.

World leaders in technology and instrumentation partner with INNOVA to optimize your diagnosis and management of retinal disease.



D.O.R.C. has over 30 years of experience developing new innovative products setting the standard for retinal surgery.



Heidelberg Engineering's Spectralis imaging platform provides unparalleled view and accuracy of the retina and retinal vasculature.



NIDEK's solid-state lasers, and their new VIXI pattern photocoagulator, make laser treatments accurate and easy.



OCULUS' BIOM and SDI have earned their position as the gold standard for surgical retina observation.

**INNOVA** Contact us today at [info@innovamed.com](mailto:info@innovamed.com) or 800-461-1200



**Labtician Ophthalmics, Inc.** is a solutions focused provider of specialty innovative medical device and pharmaceutical products to the Canadian Ophthalmic community. We are a world leader in supplying surgical products and accessories for retinal surgery.

Labtician provides the retinal community with reliable service and high quality products from our exclusive commercial partners including Fluoron and Beaver-Visitec International, Inc. Our alliance with Synergetics means Labtician can also offer precision engineered microsurgical instruments, capital equipment and devices primarily for use in vitreoretinal surgery to service the needs of our Canadian retinal surgeons.

Polydor Strouthos  
Tel: 905-829-0055  
email - [pstrouthos@labtician.com](mailto:pstrouthos@labtician.com)  
[www.labtician.com](http://www.labtician.com)

**Ophthalmic Direct's** service is underpinned by GMD's strengths in cold chain distribution, customer service, and stakeholder management.

Ophthalmic Direct offers a unique direct distribution channel for specialty ophthalmic products via our partnering network of ophthalmology clinics across Canada.

Through our direct distribution model we ship products directly to ophthalmologist's offices where we also set up and manage the infrastructure required for proper storage and handling.

Ophthalmic Direct fosters close working relationships with all stakeholders in the process, thereby allowing for seamless care. Our team of dedicated specialists ensures that product supplies are available at clinics when they are needed and also help patients navigate the often cumbersome insurance process needed to obtain coverage.

Our growing presence in Canada positions us uniquely to help our clients to put their product directly into the hands of leading ophthalmologists across the country.

Sally Bibic  
Tel: 289-242-8238  
email - [sbibic@ophthalmicdirect.ca](mailto:sbibic@ophthalmicdirect.ca)  
[www.ophthalmicdirect.ca](http://www.ophthalmicdirect.ca)



Medical Pharmacies Group Limited (MPGL) and its wholly owned subsidiary, OMS, are proud to be a corporate sponsor of this year's Canadian Retina Society Meeting.

As a leading Canadian provider of specialty pharmacy and healthcare products and services, our core focus is on supporting patients and healthcare providers across all care settings to achieve optimal health outcomes.

Medical Pharmacies' Specialty division provides customized pharmacy and patient support services that enhance Ophthalmology practice efficiency, patient convenience and safety. Our Med-e-Consult Patient Assistance and Specialty Pharmacy teams work closely with specialists' offices, administration clinics, hospitals, long term care institutions and other stakeholders to simplify the ordering, delivery, administration and reimbursement of specialized ophthalmic treatments and other specialty drug therapies treating a wide range of chronic conditions.

Services include:

- Specialty Pharmacy Support
- Infusion and Injectable Therapy Preparation
- Medical Supplies, Procedure Kits, Equipment
- Med-e-Consult Patient Assistance Services
- Clinic Administration and Support
- Institutional Pharmacy Services
- Cold Chain Pharmaceutical Logistics & Inventory Management



Call us today to learn more about Medical Pharmacies' Specialty Services  
1-855-710-8499 • [medicalpharmacies.com/specialty-pharmacy](http://medicalpharmacies.com/specialty-pharmacy)



Is proud to sponsor the 2015  
Canadian Retina Society meeting.

[www.SalientMed.com](http://www.SalientMed.com)

Email: [info@salientmed.com](mailto:info@salientmed.com)

Phone: 855-736-3003

*We are the exclusive Canadian distributor for*



# PROGRAM AT A GLANCE



## LEARNING OBJECTIVES

Describe the identification and treatment of both common and rare medical and surgical diseases of the retina

Describe the testing and treatment recommendations for patients with retinoblastoma

Describe the current practice patterns of Canadian retina specialists

## Thursday, February 26

**1200-1600 Arrivals**  
Industry advisory boards

**1620-1725 Scientific session #1**  
Mystery cases – *Various presenters*

**1730-1900 CRS Business Meeting**

**1900-2030 Welcome Reception**

## Friday, February 27

**0600-0630 Breakfast**

**0630-0900 Scientific session #2**  
Vitreoretinal lymphoma – *Dean Elliott*  
Diabetic retinopathy: current and investigational therapies – *Allen C. Ho*  
Anti-VEGF switch cases – *Various presenters*

**0900 Refreshment break**

**0910-1010 Co-developed symposium (Bayer sponsored)**  
Multidisciplinary care of diabetic macular edema – *David Maberley, Alice Y.Y. Cheng, and Peter J. Lin*

**1530-1600 Refreshment break**

**1600-1830 Scientific session #3**  
Ocular management of trauma – *Dean Elliott*  
Medical management of PVR – *Dean Elliott*  
An individualized approach to post-traumatic exploratory vitrectomy in children and young adults – *Theodor Stappler*

Molecular design for novel ocular tamponades – *Theodor Stappler*

Management of complex retinal detachment: panel discussion

**1900-2200 Dinner**

## Saturday, February 28

**0600-0630 Breakfast**

**0630-0900 Scientific session #4**  
Cell therapy for age-related macular degeneration – *Allen C. Ho*

The Argus® II Retinal Prosthesis for severe retinitis pigmentosa – *Allen C. Ho*

Subretinal implants: surgical challenges and visual outcomes – *Florian Gekeler*

Surgical and pharmacological effects on the vitreoretinal interface – *Theodor Stappler*

**0900 Refreshment break**

**0910-1010 Co-developed symposium (Alcon sponsored)**  
Management of macular holes 2015 – *Netan Choudhry, Allen C. Ho, David Chow, Michael Kapusta*

**1530-1600 Refreshment break**

**1600-1830 Scientific session #5**  
Dr. Mila Oh Memorial Lecture: One Retinoblastoma World: a consortium for optimized care everywhere – *Brenda L. Gallie*  
The desperate need for evidence in quality care for retinoblastoma – *Brenda L. Gallie*  
Why is there cataract after vitrectomy? – *Florian Gekeler*  
High-altitude ophthalmology – *Florian Gekeler*

**1900-2000 Ice Bar**

## Sunday, March 1

**0630-0700 Breakfast**

**0700-1000 Scientific session #6**  
Expanding the dialogue Result of the Canadian Preferences and Trends (CAN-PAT) Survey – *Jim Whelan and Netan Choudhry*  
Interesting surgical cases – *Various presenters*

**1000 Adjourn**